$CORT

Corcept (CORT) reported Q2 revenues of $256.1M, up 31.7% YoY, beating estimates. Zoetis (ZTS) reported flat revenues of $2.47B, missing expectations. Bristol-Myers Squibb (BMY) reported $12.97B in revenues, up 5.7% YoY, beating estimates. Eli Lilly (LLY) reported $22.97B in revenues, up 47.7% YoY, beating estimates. Market focus has shifted from AI to geopolitics and back to fundamentals.

Corcept Therapeutics (CORT) reported positive Phase 2 BELLA trial results for Lifyorli with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer, showing a median PFS of 7.2 months and ORR of 59%. Median OS data was not yet available. The results support Lifyorli's potential in this indication, according to the company.

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

WILSON JAMES N sold 10,000 indirectly-held shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $114.81 ($114.48–$116.30, $1.15M total) across 3 trades on 2026-10-15 under a Rule 10b5-1 trading plan.

Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.10 ($114.52–$116.58, $0.97M total) across 3 trades on 2026-10-02 under a Rule 10b5-1 trading plan.

Lyon Joseph Douglas (See Remarks) sold 10,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.07 ($115.40–$116.54, $1.16M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

Maduck Sean (See Remarks) sold 25,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.26 ($115.54–$116.55, $2.91M total) across 3 trades over 2026-10-01 to 2026-10-02 under a Rule 10b5-1 trading plan.

JPMorgan BetaBuilders U.S. Small Cap Equity ETF (BBSC) added 171 positions on Monday, deploying $161.2 million in net purchases. Its largest buys were Corcept Therapeutics (CORT) at $3.3 million, Elastic NV (ESTC) at $2.2 million, and SentinelOne (S) at $2.2 million. BBSC holds 804 stocks with a 0.09% expense ratio and a 14.66% year-to-date return.

Blue Orca and Iceberg Research published reports on EquipmentShare.com (EQPT) and Deep Fission (FISN), alleging financial and operational issues. EquipmentShare disputes the claims. Viceroy and Scorpion Capital raised concerns about Blue Moon Metals (BMM) and Twist Bioscience (TWST). Several companies, including Corcept Therapeutics (CORT), Nutanix (NTNX), and Zscaler (ZS), reported executive departures. Michael Burry warned of $3 trillion in AI-related commitments across major tech firms.

CORCEPT THERAPEUTICS INC (CORT) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 CONTACT: Investor inquiries: ir@corcept.com Media inquiries: communications@corcept.com www.corcept.com Corcept Announces Planned Leadership Transition Sean Maduck to Retire; Justin Gunn Appointed President, Endocrinology REDWOOD CITY, Calif. – September 23, 2026 – C